Prostate cancer – and perhaps other cancers – promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research.
Previous research showed that prostate cancer follows the growth of nerves, but this is the first time that scientists have demonstrated that the tumors actually promote nerve growth.
Inactivating a specific biomarker for aggressive prostate cancer, called GRP78, blocks the development of prostate cancer in animal models according to researchers at the University of Southern California (USC). This breakthrough discovery may lead to a novel cancer therapy for humans.
Magnetic resonance-guided focused ultrasound surgery (MRgFUS), a noninvasive thermal ablation technique that has been shown to be clinically effective in the treatment of uterine fibroids, is now being evaluated as a method for treating painful bone metastases.
Now physicians in North America are running a full scale clinical trial to see if the method really does work as well or better than traditional pain management methods.
When men should take their first PSA test to screen for prostate cancer is an issue that comes up constantly in discussions of mens’ health.
The National Comprehensive Cancer Care Network (NCCN) recommends men to take their first PSA test at age 40. How soon and how often to take a follow-up PSA tests would then depend on this initial level.
Harping on negative consequences of a lack of cancer screening among minorities can actually make African-Americans less likely to go for screening, according to behavioral science research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
New effort to find out if anti-cholesterol drugs can help reduce men’s risk of prostate cancer
Popular cholesterol-busting drugs called statins appear to lower men’s PSA values along with their cholesterol levels according to researchers in the Duke Prostate Center and the Durham Veterans Affairs Medical Center. But whether the drugs prevent prostate cancer growth or just mask it is not known yet.
Men with prostate cancer caused by a faulty BRCA2 gene are more than twice as likely to die from the disease than those carrying the faulty BRCA1 gene – reveals a study published in the British Journal of Cancer June 24 2007.
These findings could help tailor treatment and target chemotherapy more effectively to men with prostate cancer that is caused by a BRCA gene fault.
Active Surveillance for Low-Risk Prostate Cancer Demands Careful Selection, Study Says
Active surveillance followed by selective treatment for men who have evidence of disease progression may be an option for some patients with early-stage prostate cancer.
Miami Team Finds Most Low-Risk Patients Stay Treatment-Free for Five Years
For men diagnosed with low-risk prostate cancer, active surveillance can be a sensible first step in managing the disease. Mark Solloway and a team of urologists at University of Miami Miller School of Medicine have reported on outcomes for a group of their patients.
For Slow Growing Prostate Cancer Delay May be Reasonable, Hopkins Study Finds
Delaying surgery — even for years — for patients with small, low-grade prostate cancer does not appear to increase the risk of the disease progressing to an incurable form, according to a 10-year Johns Hopkins Medicine study. This discovery could prevent over-treatment, the authors say.